Genetic Technologies Limited
GENE
$0.765
-$0.015-1.92%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.44% | -16.66% | -40.72% | -45.00% | -52.83% |
| Total Depreciation and Amortization | -23.00% | -14.23% | -4.13% | 1.21% | 8.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.18% | 192.27% | 1,240.02% | 491.50% | 127.57% |
| Change in Net Operating Assets | 167.46% | 46.59% | -335.05% | -335.05% | -335.05% |
| Cash from Operations | 2.88% | 3.41% | 3.09% | -22.50% | -58.65% |
| Capital Expenditure | -83.05% | -92.25% | -100.71% | 34.11% | 74.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | 100.00% | 88.63% | 86.89% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.15% | 40.93% | 230.95% | 464.66% | 4,869.23% |
| Cash from Investing | 136.03% | 139.56% | 142.18% | 97.22% | 91.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.69% | 8.52% | 18.30% | 1.31% | -25.24% |
| Issuance of Common Stock | -64.07% | 35.93% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.26% | 0.15% | -8,728.85% | -8,718.27% | -8,707.69% |
| Cash from Financing | -53.55% | 54.95% | 1,427.08% | 1,686.40% | 2,090.70% |
| Foreign Exchange rate Adjustments | -136.76% | -66.63% | 196.29% | 36.32% | -5.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -72.90% | 36.40% | 86.18% | 73.60% | 61.30% |
